Your vote is important!
Please vote your proxy online now or by dialing 866-240-5352.
June 11, 2024
9:00 a.m. Eastern Time
vTv Therapeutics is a clinical stage biopharmaceutical company focused on developing oral, small molecule drug candidates.
vTv has a pipeline of clinical drug candidates led by cadisegliatin (TTP399), a potential adjunctive therapy to insulin for the treatment of type 1 diabetes. vTv and its development partners are pursuing additional indications, including type 2 diabetes and other chronic conditions.